Business Context and Reporting Period
This is Pieris Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2018; it is not a filing for Palvella Therapeutics, Inc., the company identified in the request metadata. Pieris is a clinical-stage biopharmaceutical company developing Anticalin-based therapeutics. It reported no product sales; revenue came primarily from licensing and collaboration agreements.
Financial Highlights
| Metric | Q2 2018 | Six months ended June 30, 2018 |
|---|---|---|
| Revenue | $11.7 million | $15.8 million |
| Research and development expense | $9.2 million | $17.1 million |
| General and administrative expense | $4.8 million | $9.1 million |
| Operating loss | $2.2 million | $10.4 million |
| Net loss | $0.2 million | $8.9 million |
| Operating cash flow | Not presented by quarter | $22.4 million provided |
Revenue increased from $1.9 million in Q2 2017 and $3.2 million in the first half of 2017. Net loss narrowed from $10.1 million and $18.1 million, respectively. Revenue growth primarily reflected activity under the AstraZeneca and Servier collaborations and the new Seattle Genetics agreement. Q2 results also included $0.7 million of interest income and $1.2 million of other income; the latter was mainly foreign-currency gains. The filing does not provide a meaningful product gross margin, as Pieris had no product sales.
At June 30, cash and cash equivalents were $50.6 million, short-term investments $100.4 million, and long-term investments $0.7 million, for total cash, cash equivalents, and investments of $151.7 million. Current assets were $156.6 million versus current liabilities of $52.3 million. Total liabilities were $106.7 million, principally deferred revenue; the filing reports no material debt balance. Operating cash flow included substantial collaboration receipts and working-capital movements. Investing cash outflow was $57.1 million, largely reflecting investment purchases; financing cash inflow was $48.2 million, primarily from the February public offering.
Material Changes, Outlook and Risks
- In February 2018, Pieris raised approximately $47.6 million net from an offering of 6.325 million shares at $8.00 per share.
- The Seattle Genetics collaboration began in February 2018. It included a $30.0 million upfront payment and estimated research reimbursements of $4.9 million. Potential payments are contingent on development and commercial outcomes; the company cited up to $1.2 billion in success-based milestones under this agreement.
- Management expected existing cash, cash equivalents, and investments to fund operating and capital requirements for at least 12 months from the filing date. It also expected substantial losses and rising development costs for several years. Additional capital may be needed, and financing could be difficult or dilutive.
- Management planned to report initial PRS-343 Phase I data and PRS-060 Phase I data in Q4 2018, report PRS-080 Phase IIa data in the second half of 2018, initiate a PRS-343 combination study with atezolizumab in the second half of 2018, and file two immuno-oncology INDs in 2019. These are forward-looking plans, not reported outcomes.
- Roche notified Pieris that its collaboration would terminate effective August 21, 2018; Sanofi’s agreement was to terminate effective August 23, 2018. Pieris expected returned program data and materials and said it would assess strategic options. The separate Roche drug-supply arrangement for a planned study was not affected.
- Discussions with the Technical University of Munich could increase Pieris’s financial obligations, including amounts relating to 2017 and 2018 activities; the potential impact was not estimable and no amended agreement had been completed.
- Disclosure controls and procedures were deemed ineffective due to a previously reported material weakness in the financial-statement close process, involving expense classification and foreign-currency remeasurement. Remediation was underway but was not yet considered complete.
Important Facts for Investors to Verify
- Confirm the issuer identity: this filing is for Pieris Pharmaceuticals, Inc., not Palvella Therapeutics, Inc.
- Track actual clinical data, trial timelines, and whether planned milestones and IND filings were achieved.
- Assess collaboration revenue recognition and the timing, conditions, and likelihood of contingent milestones; potential milestone amounts are not guaranteed revenue.
- Monitor cash use, investment liquidity, collaboration receipts, and whether the stated 12-month runway remains adequate as development spending rises.
- Follow the Roche and Sanofi program transitions, TUM agreement discussions, and progress in remediating the material weakness in disclosure controls.